Form 4: Director Wayne Riley Receives Stock Options in CMPS

COMPASS Pathways plc director Wayne Riley was granted 21,110 stock options as part of standard equity compensation.

Summary

• Director Wayne Riley was granted 21,110 share options on May 27, 2026.
• The options have an exercise price of $11.85 per share.
• The options vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual General Meeting.
• The options expire on May 26, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market price volatility may impact the future value of the granted options.
• The value of the options is contingent upon the company's future share price performance relative to the $11.85 strike price.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the equity compensation of a director.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard practice in the biotechnology sector to attract and retain board talent, aligning leadership with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The vesting schedule (one year or next AGM) is consistent with standard corporate governance practices for non-executive director compensation in the UK and US biotech markets.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on May 27, 2027, or the date of the 2027 Annual General Meeting.

Key Dates

Keywords

COMPASS Pathways, CMPS, Director Compensation, Stock Options, Insider Transaction, Biotech